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Background: The study investigated if a web-based clinical decision–support system 
(CDSS) tool would improve general practitioners’ (GPs) accuracy of diagnosis and classi-
fication of patients with chronic obstructive pulmonary disease (COPD), and whether non-
pharmacological and pharmacological treatment would be better aligned with the COPD 
guidelines.
Methods: GPs were randomized to either a single use of the CDSS or continuing standard 
of care. The clinical recommendations of the CDSS were based on the GOLD guidelines and 
provided suggestions for treatment and management of COPD. Data were collected digitally 
from GPs and patients in both groups using a tablet computer. A follow-up questionnaire was 
sent to the GPs 1 year after the conclusion of the study.
Results: A total of 25 GPs (31% women, mean age 41 years) participated, 12 randomized to 
using the CDSS tool and 13 followed standard of care when assessing their next five to ten 
COPD patients. In sum, 149 patients with presumed COPD were included (88 CDSS group, 
61 standard-of-care group). In the CDSS group, no COPD misdiagnoses occurred, 98% 
received vaccine recommendations, and all smokers (n=39) received smoking-cessation 
advice. The standard-of-care group had 23% misdiagnosis (P<0.001), only 67% received 
vaccine recommendations (P<0.001), and 87% smoking-cessation advice (P=0.022. All told, 
31% of patients did not receive medication as recommended according to guidelines, with no 
significant differences between the groups. GPs rated the CDSS as very useful. Mean usage 
time was 3 minutes, 26 seconds. A majority (13 of 19, 68%) of the GPs continued using the 
CDSS after the conclusion of the study. CAT score identified twice as many patients as 
having more symptoms than the mMRC, indicating the added value of the multi-item 
questionnaire.
Conclusion: Use of the CDSS was associated with preventing misdiagnosis of COPD and 
improved adherence to recommended nonpharmacological measures, but a single use did not 
improve pharmacological treatment considerations.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable and modifiable 
condition characterized by irreversible or poorly reversible airflow obstruction and 
persistent respiratory symptoms due to airway and/or alveolar abnormalities. The 
disease is caused by prolonged exposure to noxious particles or gases, primarily 
from cigarette smoking.1 COPD contributes heavily to the morbidity and mortality 
rate worldwide. In 2019, it was the third–most common cause of all deaths 
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globally, with over 3 million fatalities,2 accounting for 
6% of all deaths. In a population-based study in Norway 
in people aged >40 years performed in 2015–2016, 6% 
had COPD using the lower limit of normal of forced 
expiratory volume in 1 second (FEV1)/forced vital capa-
city (FVC) ratio and the Global Lung Index 2012,3 corre-
sponding to 150,000 people. However, only half are 
currently receiving treatment for COPD according to the 
national prescription database, reflecting that a significant 
proportion are being undiagnosed, as is also seen in many 
other countries.4,5 This discrepancy could be related to 
several factors. One may be that general practitioners 
(GPs), the primary caregivers for patients with COPD, 
are overwhelmed by a rising number of different national, 
regional, and international guidelines across many differ-
ent disease-areas for diagnostics, treatment, and follow- 
up, which increases the risk of information overload for 
physicians and risk of clinical inertia.6
As early diagnosis of COPD is recommended7 and 
establishing early-management strategies and initiating 
treatment has been seen to reduce both morbidity and 
mortality,8 tools to support GPs in identifying and mana-
ging people with COPD are needed, and a clinical deci-
sion–support system (CDSS) could be one.
CDSSs have various definitions. An early paper in 
clinical decision-making defined a CDSS as software that 
analyzes clinical information and presents conclusions 
(guidelines) for clinicians as output information.9 The 
input may be patient symptoms or results of lab or imaging 
investigations. Generated output may be diagnostic or 
therapeutic recommendations. Previous interventions with 
CDSSs have shown that if utilized successfully, such tools 
may increase adherence to evidence-based guidelines, 
reduce health-care costs, lead to a reduction in unneces-
sary diagnostic procedures being performed, and reduce 
inappropriate pharmacological treatment.10–12 CDSSs have 
been used in the diagnosis and management of chronic 
conditions such as hypertension,13 deep-vein thrombosis,14 
asthma,15 and type 2 diabetes.16,17 A meta-analysis of 
a range of studies investigating the use of a CDSS on 
patients with asthma showed a positive impact of the 
intervention on management of the disease.18 At least 
two studies using CDSSs in managing acute exacerbation 
of COPD in the emergency department19,20 have been 
published, whereas there is a lack of studies investigating 
the impact of CDSSs at the primary-care level for mana-
ging stable COPD.
The present study explored the feasibility of an 
existing web-based CDSS tool for COPD in general 
practice. Our main goal was to investigate if such 
a tool would improve the accuracy of diagnosis and 
classification of COPD patients and whether nonphar-
macological, and pharmacological treatment were 
aligned with COPD guidelines.
Methods
Participants
GP group practices with four or more doctors within 
a 16 km radius of Haukeland University Hospital, 
Bergen, Norway were invited personally in 
March 2019. Bergen has a population of approximately 
275,000 and 238 GP practices. The GPs were rando-
mized into two groups, one using an online digital 
CDSS for decision support, the other continuing to pro-
vide standard of care without the CDSS. Both groups 
were asked to include their next 5–10 patients with 
newly diagnosed or established COPD to participate in 
the study. A follow-up questionnaire was sent to the GPs 
1 year after the conclusion of the study. Written informed 
consent was obtained from all patients and also from the 
GPs who completed the follow-up questionnaire. The 
study was approved by the Regional Committees for 
Medical and Health Research Ethics (REK 2018/947) in 
Norway and performed in accordance with the 
Declaration of Helsinki. A flowchart illustrating inclu-
sion of patients and GPs for the study is shown in 
Figure 1.
About the Digital CDSS
The digital CDSS was based on the 2019 Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) guidelines 
and the Norwegian COPD guidelines from 2012. The 
CDSS was developed by our group in cooperation with 
the Norwegian Heart and Lung Association. While the 
CDSS has been freely available for use since 2014, its 
use has not been widespread. For the purpose of the study, 
the existing web-based CDSS was customized to a “study 
version” for data-collection purposes. In addition, data 
were collected digitally using a tablet in both groups, 
transferring anonymized data to a secure study database. 
For the control arm, all information was collected on the 
tablet.
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Data Collection and System Feedback for 
GPs Using the CDSS
GPs entered patients’ sex, age, ethnicity, height, weight, 
smoking status, number of exacerbations requiring oral 
steroids and/or antibiotics or hospitalization the past year, 
modified Medical Research Council (mMRC) dyspnea- 
scale score,21 and COPD-assessment (CAT) test score.22 
During the clinic visit, all patients underwent spirometry 
and had FEV1 and FVC recorded.
The system-generated feedback to the GP included 
a summary of the results in a tabulated manner. If spirometry 
were consistent with airflow obstruction, defined as having 
an FEV1/FVC ratio <0.7 or below the lower limit of normal 
using the Global Lung Index 2012,3 a diagnosis of COPD 
was reported as “probable” under the condition that airflow 
obstruction was persistent. The severity of airflow limitation 
and the ABCD patient group according to the GOLD guide-
lines was also provided.1 If no obstruction was found on 
spirometry, the COPD diagnosis was labelled “unlikely”, 
with spirometry feedback as either “normal” or as “restrictive 
pattern”.
Treatment advice based on the GOLD ABCD group for 
each individual patient was provided, ie, first-line medication 
and additional medication suggestions in cases of symptoms 
of dyspnea or exacerbations. Finally, a summary of other 
COPD-management topics (smoking-cessation 
Figure 1 Flowchart illustrating inclusion of both general practitioners (GPs) and patients with chronic obstructive pulmonary disease (COPD) in the study. Feedback from 
the digital clinical decision–support system (CDSS) prevented inclusion of screen failures among GPs using the CDSS if spirometry did not show airway obstruction.
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recommendations in smokers, physical exercise, pulmonary 
rehabilitation, and flu vaccination) was listed. At the end of 
the consultation, the GP handed over the tablet to the patients 
to complete the study questionnaires.
Data-Collection Procedures for GPs Not 
Using the CDSS
At the end of a COPD consultation, the GP filled out 
spirometry results and current medication used for COPD 
on the tablet and then handed it over to the patient to 
complete the study questionnaires.
Patient-Reported Data
The study questionnaires included mMRC dyspnea-scale 
and CAT scores, questions on exacerbation history, physi-
cal activity habits, and smoking status. All patients were 
asked if they had received information on physical activ-
ity, pulmonary rehabilitation, and/or flu vaccination during 
the consultation. Current smokers were asked if smoking 
cessation had been discussed.
Follow-Up Data from GPs
A follow-up questionnaire was sent to the GPs 1 year after 
conclusion of the study, where we asked for their age, 
sex, year of obtaining medical license, if they had used the 
CDSS following the completion of the study, and if that 
were the case, how useful they found it on a scale from 
1–10.
Definition of Adherence to GOLD 
Guidelines
Categorization in GOLD treatment groups was based on the 
degree of symptoms evaluated by both CAT and mMRC 
scores, in addition to exacerbation history.1 We defined 
appropriate medication as receiving medication as described 
by the GOLD ABCD medication group with/without add- 
ons for dyspnea and/or exacerbations, and “undertreated” if 
receiving less treatment. Patients were considered treated 
outside the GOLD guidelines if they were prescribed oral 
corticosteroids in stable COPD, inhaled corticosteroids (ICS) 
in a mono-inhaler, PDE4 inhibitor when FEV1 >50%, two or 
more drugs belonging to the same medication class, if using 
both a short and a long-acting muscarinic antagonist, and if 
using montelukast for COPD.
Definition of Misdiagnosis of COPD
If no obstruction was found on spirometry, the diagnosis of 
COPD was considered misdiagnosed.
Statistical Analysis
Statistical analysis was performed using SPSS 26. Data are 
presented as means ± SD, medians and quartiles, or per-
centages. Independent-sample t-tests used for comparing 
data with normal distribution, while nonparametric data 
were compared with independent-sample Mann–Whitney 
U and Chi-square tests.
Results
Figure 1 shows the study design. Of 36 GPs invited, 25 
participated: 13 were randomized to use the CDSS (31% 
women, mean age 41 years) and 12 to continue standard of 
care without the CDSS (33% women, mean age 50 years). 
In sum, 149 patients were included: 88 in the CDSS group 
(37 women, mean age 72 years) and 61 in the control 
group without the digital CDSS (30 women, mean age 
68 years). Nineteen GPs (76%) completed the follow-up 
questionnaire 1 year after the study.
Table 1 shows the characteristics of the GPs and patients 
in the intervention and control groups. Characteristics of the 
patients were mostly comparable. Only 77% in the control 
group had obstructive spirometry consistent with COPD. In 
patients without obstructive spirometry, eleven had normal 
spirometry, while three had lung volumes lower than the 
lower limit of normal, consistent with a restrictive spirome-
try (not shown in table). The COPD patients had mean 
FEV1 of 1.5L (0.7) and FVC 2.8L (1.0). Median CAT 
score was 13 (9). Characteristics of misdiagnosed patients 
were comparable for most COPD patients, differing only in 
spirometric results, with mean FEV1 2.8L (1.3) and FVC 
3.1L (1.3; Table 2).
Nineteen GPs (76%) completed the follow up ques-
tionnaire. Six in the non-CDSS group had misdiagnosed 
one or more patients. GPs who had included misdiagnosed 
patients were younger (mean age 35±7 years), and had had 
their license to practice medicine for a shorter period (5.3 
±2.9 years) than GPs with no misdiagnosis: mean age 45 
±11 years, had had medical license 17±10 years (P=0.05).
Symptom-Questionnaire Assessment
A moderately strong positive correlation was found 
between mMRC and the CAT symptom scores (r=0.47, 
Figure 2). However, self-reported dyspnea on the mMRC 
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questionnaire identified only 51 patients (34%) as sympto-
matic (mMRC score ≥2), while the composite CAT score 
(CAT ≥10), identified 110 patients (73%) as symptomatic. 
Different proportions of patients in each ABCD treatment 
group were found on the CAT and mMRC (Figure 3). On 
the mMRC, 59% were defined as group A. With the CAT 
score, this group was reduced to 27%, leaving group B as 
the most represented — 55%. On CAT scores, group 
C was almost eliminated.
Pharmacological Treatment
Pharmacological treatment with the various COPD medi-
cations is presented in Table 1. There were no notable 
differences in prescription patterns between the two 
groups, although patients in the control group were pre-
scribed short-acting muscarinic antagonists (SAMAs) 
more often (15% versus 5%). Figure 4 shows how medi-
cation was prescribed in the medication groups. In group 
A and B, some patients were not on any medication for 
COPD. Most patients in group C and D were on inhaled 
ICS. Almost a third (30%) of the patients were incorrectly 
medicated according to GOLD guidelines, with no signifi-
cant differences between the groups (Figure 5). Most 
Table 1 Characteristics of patients and GPs in the intervention 
and the control groups
Intervention Control P
n 88 61
Age (years) 72 (9) 68 (9) 0.014
Height (cm) 168 (9) 171 (9) NS
Women 59% 49% NS
Current smokers 44% 38% NS
FEV1 (L) 1.5 (0.6) 1.9 (1.0) NS
FVC 2.6 (0.9) 3.0 (1.2) NS
FEV1/FVC 0.57 (0.11) 0.61 (0.19) NS
mMRCa 1 (1) 1 (1) NS
CATa 12 (8) 15 (10) 0.019
Exacerbationsa 0 (1) 0 (1) NS
Obstructive spirometry 100% 77% <0.001
Drug class
SABA 46 (52%) 40 (66%) NS
SAMA 4 (5%) 9 (15%) 0.030
LABA 60 (67%) 44 (72%) NS
LAMA 65 (73%) 38 (62%) NS
ICS 46 (52%) 27 (44%) NS
GP characteristics
nb 9 10
Age (years)b 49 (12) 39 (9) NS
Womenb 33% 40% NS
Clinical experienceb 17 (12) 11 (8) 0.023
Number of patientsb 8 (4) 5 (1) NS
Notes: Intervention group defined as GPs using the digital clinical decision–support 
system (CDSS). The control group continues standard care without the CDSS. Data 
presented as means (SD) unless otherwise, stated. aMedian (IQR). bOnly GPs who 
answered the follow-up questionnaire and provided signed consent. 
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; mMRC, modified Medical Research Council (dyspnea scale); CAT, COPD- 
assessment test; SABA, short-acting beta 2 agonist; SAMA, short-acting muscarinic 
antagonist; LABA, long-acting beta 2 agonist; LAMA, long-acting muscarinic antago-
nist; ICS, inhaled corticosteroid.
Table 2 Comparison of characteristics between COPD and 
misdiagnosed patients
COPD Misdiagnosed P
Subjects (n) 135 14
Age (years) 71 (9) 67 (11) 0.014
Height (cm) 169 (9) 169 (10) NS
Women 55% 57% NS
Current smokers 42% 36% NS
FEV1 (L) 1.5 (0.7) 2.8 (1.3) <0.001
FEV1 (% predicted) 58 (21) 99 (26) <0.001
FVC (L) 2.8 (1.0) 3.1 (1.3) NS
FEV1/FVC 0.56 (0.11) 0.87 (0.10) <0.001
mMRCa 1 (1) 1 (1) NS
CATa 13 (9) 16 (11) NS
Exacerbationsa 0 (1) 0 (2) NS
GP characteristics
n 13 6
Age, yearsb 45 (11) 35 (7) 0.004
Womenb 37% 50% NS
Clinical experience† 17 (10) 5.3 (2.9) <0.001
Notes: Data presented as means ± SD unless otherwise stated. aMedian (IQR). 
bOnly GPs who answered the follow-up questionnaire and provided signed consent. 
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; mMRC, modified Medical Research Council (dyspnea scale); CAT, COPD- 
assessment test; GP, general practitioner.
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commonly, they were undertreated (17%), receiving ICS 
in a mono-inhaler (8%), or receiving two medications 
belonging to the same group of drugs (7%). Two patients 
were on oral corticosteroids and an ICS mono-inhaler.
Nonpharmacological Interventions
A comparison of nonpharmacological interventions 
between the two groups is shown in Table 3. Significant 
differences between the groups were observed for flu 
vaccination and smoking-cessation recommendations. 
All current smokers in the intervention group were 
offered smoking-cessation advice and 98% flu- 
vaccination advice compared with 87% for smoking 
cessation and 67% for vaccine recommendations in the 
control group.
User Satisfaction with the CDSS
Mean time from first input until the GP reached the result page 
in the CDSS group was 3 minutes, 26 seconds. After the 
conclusion of the study, 13 of 19 (68%) GPs were still using 
the CDSS, including several GPs in the control group. On the 
usefulness scale (1–10), the CDSS received a mean rating of 
8.6±1.3. Table 4 shows the characteristics of GPs who con-
tinued to use the digital CDSS after study conclusion. GPs not 
using the CDSS after study conclusion were significantly older 
and had had their medical license longer (P=0.05, Table 4).
Figure 3 GOLD ABCD treatment groups in COPD patients defined by COPD-assessment test (CAT) score and bmodified Medical Research Council (mMRC) dyspnea- 
scale score, with misdiagnosed patients excluded (n=135).
Figure 2 (A) Correlation between COPD-assessment test (CAT) and modified Medical Research Council (mMRC) dyspnea-scale scores (n=149, r=0.47; P<0.001. (B) 
Distribution of CAT scores (median) according to mMRC score. Error bars represent the interquartile range.
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Discussion
We investigated if a digital CDSS could increase GP 
adherence to guidelines for treating patients with COPD. 
The intervention prevented misdiagnosis and improved 
adherence to the nonpharmacological measures of smok-
ing cessation and flu vaccination, but did not show 
a difference on pharmacological considerations used at 
a single visit.
Figure 5 Pie chart showing medication among the patients. Appropriate medication defined as receiving medication as described by the GOLD ABCD medication group 
with/without add-ons for dyspnea and/or exacerbations. 
Abbreviations: ICS, inhaled corticosteroid; PDE4, phosphodiesterase-4 inhibitor; OCS, oral corticosteroid.
Figure 4 Medication use in the GOLD ABCD treatment groups generated using the COPD- assessment test for symptom evaluation. 
Abbreviations: BD, bronchodilator; ICS, inhaled corticosteroid.
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The CDSS helped GPs in interpreting spirometry 
results and prevented misdiagnosis in the intervention 
group. We do not know the exact number of screen failures 
in the CDSS group, as very few GPs provided this infor-
mation, but feedback from the CDSS prevented these 
patients from being included as COPD patients. Most 
patients who were misdiagnosed in the control group had 
completely normal spirometry, but shared a similar burden 
of respiratory symptoms to the COPD patients. This may 
have contributed to misdiagnosis. GPs with the shortest 
medical professional career had more COPD misdiag-
noses, which may reflect better diagnostic skills with 
longer experience, although more seasoned GPs also sim-
ply may know their patients better.
The intervention did improve adherence to the non-
pharmacological recommendations of smoking cessation 
and flu vaccination. Smoking cessation, vaccinations, phy-
sical activity, and pulmonary rehabilitation play important 
roles in the long-term management of the illness and 
treatment outcomes. In a busy everyday practice, these 
recommendations may be forgotten. Showing this infor-
mation on the summary screen of the CDSS proved to be 
an effective reminder of nonpharmacological 
recommendations.
A third of the patients were either undertreated or 
received medication not recommended by the GOLD 
guidelines. There were no differences in pharmacological 
management between the groups, apart from less SAMA 
use in the intervention group. It is possible that the visual 
presentation on-screen was not perceived as important 
enough by the GPs to justify a change in medication or 
that the low number of participants made the study too 
underpowered to find such a difference. This might not 
have been a visit where the GP found it necessary to 
change medication. It is plausible that the lower prescrip-
tion of SAMAs in the intervention group was due to 
treatment advice provided by the digital CDSS. If 
a patient had already received a long-acting muscarinic 
agonist (LAMA), a “stop” sign would appear on all 
SAMAs, indicating that no additional effect of a SAMA 
could be expected from this drug on top of a LAMA.
As a secondary objective, we investigated question-
naires used for symptom assessment. Very different pro-
portions of patients were assigned in each ABCD 
treatment group when the mMRC scale was used com-
pared with the CAT, and only half as many were defined as 
symptomatic on the former. The mMRC scale and CAT are 
considered equal in classifying COPD patients into ABCD 
treatment groups. The eight-item CAT identified twice as 
many patients in our study as having more symptoms than 
the mMRC scale. For this reason, we suggest adding 
a multi-item questionnaire when evaluating symptoms in 
patients who otherwise are defined as having a low grade 
of symptoms by mMRC-scale score alone (<2).
Multiple studies have investigated adherence of GPs to 
COPD guidelines. There is no uniformity in the adherence of 
GPs to guidelines or recommendations.23 GP practices fre-
quently fail to document lung function in COPD patients,24– 
26 spirometry is often not performed adequately and may be 
interpreted incorrectly,27,28 and inappropriate medication is 
frequently prescribed.26,27 Such factors as lack of adequate 
knowledge and training and time constraints have been 
posited to be the major barriers.27 Educational programs 
aimed at improving GP practice in treating COPD patients 
do not seem to have a significant impact on diagnostic 
accuracy or pharmacological therapy.26
As all GPs in Norway use a computer and have an 
internet connection, a digital CDSS can easily be imple-
mented for all clinicians. The digital CDSS was quite fast 
and received high marks on usefulness. Most of the GPs 
continued using it after the study. Those who did not were 






Smoking cessationa 39 (100%) 20 (87%) 0.022
Physical activity 73 (82%) 54 (89%) NS
Pulmonary rehabilitation 13 (15%) 12 (20%) NS
Flu vaccination 87 (98%) 41 (67%) <0.001
Notes: Intervention group defined as GPs using the digital clinical decision–support 
system (CDSS). The control group continued standard care without the digital 
CDSS. aAmong current smokers, there were 39 in the intervention group and 23 
in the control group.
Table 4 Characteristics of GPs who continued using the digital 
CDSS after study conclusion
Continued use No use P
Interventiona 5 4 —
Controla 8 2 —
Womena 54% 0 0.024
Age, yearsa 39 (5) 51 (14) 0.026
Clinical experiencea 9 (4) 21 (4) 0.034
Notes: Intervention group, GPs using the CDSS. Control group, GPs giving stan-
dard care without the digital CDSS. Data presented as means ± SD. aOnly GPs who 
answered the follow-up questionnaire and provided signed consent.
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on average older and had more clinical experience. It 
could be that these physicians felt more confident in their 
clinical judgment. It is vital that the software is updated 
regularly to keep track of the latest changes in evidence- 
based guidelines and national recommendations. We also 
warn of a safety concern when using a secondary compu-
ter program in addition to a patient file system. When 
using two systems, there is always a risk that the informa-
tion in one system does not match the same person in the 
other. If integrated into the patient file system, safety 
concerns regarding identity could be avoided and data 
could be retrieved from the patient file system, reducing 
input time.
Limitations
The CDSS has been available online since 2014. While we 
have usage statistics of the web page, it does not log user 
information, so we cannot say for certain if the GPs (in 
either arm) had used it before study start. GPs invited who 
chose not to participate may have induced a selection bias. 
However, the nonparticipation was random. We do not 
suspect the patient population to be very different between 
those who participated and those who did not. Likewise, 
the selection based on proximity to the hospital and the 
low number of GPs and patients participating in the study 
may have induced selection bias and limit the general-
izability of the study. A longitudinal design would have 
been better suited to capture changes in medication, opti-
mally with a duration of at least 12 months, which is the 
maximum duration of a prescription in Norway. The cross- 
sectional design, examining the patients at a single point in 
time only, was chosen for cost and simplicity.
Conclusion
A digital CDSS tool prevented misdiagnosis of COPD in 
general practice and improved adherence to nonpharmacolo-
gical interventions of flu vaccination and smoking cessation. 
The intervention did not influence pharmacological treatment 
choices. CAT scores identified twice as many symptomatic 
patients than mMRC dyspnea-scale scores, indicating that 
a multi-item questionnaire should be added when evaluating 
symptoms in patients who otherwise are defined as having 
a low degree of symptoms by mMRC score alone.
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